138 related articles for article (PubMed ID: 20045985)
1. Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition.
Sekiguchi N; Higashida A; Kato M; Nabuchi Y; Mitsui T; Takanashi K; Aso Y; Ishigai M
Drug Metab Pharmacokinet; 2009; 24(6):500-10. PubMed ID: 20045985
[TBL] [Abstract][Full Text] [Related]
2. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
[TBL] [Abstract][Full Text] [Related]
3. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
4. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
5. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.
Rowland Yeo K; Walsky RL; Jamei M; Rostami-Hodjegan A; Tucker GT
Eur J Pharm Sci; 2011 Jun; 43(3):160-73. PubMed ID: 21540107
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
7. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
8. Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver.
Iwasaki S; Hirabayashi H; Funami M; Amano N
Xenobiotica; 2017 Jun; 47(6):488-497. PubMed ID: 27435455
[TBL] [Abstract][Full Text] [Related]
9. IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4.
Burt HJ; Galetin A; Houston JB
Xenobiotica; 2010 May; 40(5):331-43. PubMed ID: 20230210
[TBL] [Abstract][Full Text] [Related]
10. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
[TBL] [Abstract][Full Text] [Related]
11. In vivo approach for the evaluation of mechanism-based inhibition of cytochrome P450 3A in rats.
Sekiguchi N; Kato M; Takada M; Watanabe H; Higashida A; Sakai S; Ishigai M; Aso Y
Xenobiotica; 2008 Apr; 38(4):368-81. PubMed ID: 18340562
[TBL] [Abstract][Full Text] [Related]
12. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
[TBL] [Abstract][Full Text] [Related]
13. Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition.
Lee JY; Lee SY; Oh SJ; Lee KH; Jung YS; Kim SK
Chem Biol Interact; 2012 Jun; 198(1-3):49-56. PubMed ID: 22652334
[TBL] [Abstract][Full Text] [Related]
14. Higher throughput human hepatocyte assays for the evaluation of time-dependent inhibition of CYP3A4.
Li AP; Doshi U
Drug Metab Lett; 2011 Aug; 5(3):183-91. PubMed ID: 21722087
[TBL] [Abstract][Full Text] [Related]
15. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
Rakhit A; Pantze MP; Fettner S; Jones HM; Charoin JE; Riek M; Lum BL; Hamilton M
Eur J Clin Pharmacol; 2008 Jan; 64(1):31-41. PubMed ID: 18000659
[TBL] [Abstract][Full Text] [Related]
16. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
Chen J; Liu D; Zheng X; Zhao Q; Jiang J; Hu P
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):857-68. PubMed ID: 25850339
[TBL] [Abstract][Full Text] [Related]
17. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of curcumenol on human liver cytochrome P450 enzymes.
Sun DX; Fang ZZ; Zhang YY; Cao YF; Yang L; Yin J
Phytother Res; 2010 Aug; 24(8):1213-6. PubMed ID: 20148399
[TBL] [Abstract][Full Text] [Related]
19. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
20. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
